World-renowned RNA biology expert to help guide NTx’s next-generation therapeutic platforms

NTx, a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the appointment of Dr. Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University, to its Scientific Advisory Board (SAB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916399949/en/

World-renowned RNA biology expert Dr. Jeff Coller will help guide NTx’s next-generation therapeutic platforms as a member of its Scientific Advisory Board

“Jeff is a world-renowned scientist whose pioneering discoveries have fundamentally shaped the field of RNA biology,” said Dr. Jamie Coffin, President and CEO of NTx. “His expertise will be instrumental in guiding our technology as we continue to build platforms that can accelerate the future of RNA-based medicines.”

Dr. Jeff Coller is a leading authority in RNA and mRNA biology and currently serves as Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University. His pioneering research on mRNA stability and translation has reshaped the understanding of gene expression and contributed to the development of mRNA vaccines, including SPIKEVAX.

Dr. Coller previously directed the RNA Center at Case Western Reserve University and is Co-Founder of Tevard Biosciences, recipient of Pfizer’s Golden Ticket award. He is also a founding member of the Alliance for mRNA Medicines and serves on multiple scientific advisory boards.

“NTx is pioneering new ways to harness RNA biology for therapeutic innovation,” said Dr. Jeff Coller. “I am thrilled to contribute to the Scientific Advisory Board and collaborate with this outstanding team as we explore how advances in RNA and mRNA biology can be translated into breakthrough therapies that improve human health.”

About NTx

NTx, based in Rio Rancho, New Mexico, is revolutionizing biomanufacturing with cutting-edge solutions tailored to the demands of modern research and personalized medicine. NTx is developing innovative systems like NTxscribe® and NTxpress® to enable the sustainable production of mRNA and protein therapeutics, offering scalability from personalized doses to mass-market volumes. Discover how NTx is enabling the future of medicine at www.ntxbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250916399949/en/

“I am thrilled to contribute to the Scientific Advisory Board and collaborate with this outstanding team as we explore how advances in RNA and mRNA biology can be translated into breakthrough therapies that improve human health," said Dr. Jeff Coller